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Besides their use as contrast agents for ultrasound imaging, microbubbles are
increasingly studied for a wide range of therapeutic applications. In particular, their
ability to enhance the uptake of drugs through the permeabilization of tissues and
cell membranes shows great promise. In order to fully understand the numerous
paths by which bubbles can interact with cells and the even larger number of
possible biological responses from the cells, thorough and extensive work is
necessary. In this review, we consider the range of experimental techniques
implemented in in vitro studies with the aim of elucidating these microbubble-cell
interactions. First of all, the variety of cell types and cell models available are dis-
cussed, emphasizing the need for more and more complex models replicating in vivo
conditions together with experimental challenges associated with this increased
complexity. Second, the different types of stabilized microbubbles and more recently
developed droplets and particles are presented, followed by their acoustic or optical
excitation methods. Finally, the techniques exploited to study the microbubble-cell
interactions are reviewed. These techniques operate over a wide range of timescales,
or even off-line, revealing particular aspects or subsequent effects of these interac-
tions. Therefore, knowledge obtained from several techniques must be combined to
elucidate the underlying processes.VC 2016 AIP Publishing LLC.
[http://dx.doi.org/10.1063/1.4940429]
I. INTRODUCTION
The efficacy of microbubbles as ultrasound contrast agents was discovered by serendipity
in the late 1960s.1 They are now used in routine clinical practice for echocardiography and
increasingly for other indications2 including the quantification of biological parameters such as
blood perfusion rate and hypoxia,3 which are two important indicators of tumor malignancy.4
Advances in the understanding of cell and tissue-specific molecular markers have also led to
the development of functionalized microbubbles, which are currently being investigated for tar-
geted molecular imaging.5,6 Upon exposure to ultrasound, microbubbles undergo volumetric
oscillations and reradiate a secondary acoustic response of significantly higher amplitude than
the scattering that would be produced by a rigid sphere of equivalent size (2 lm in diameter).
They thus generate much stronger echoes than red blood cells (RBCs), enabling their use as a
blood pool agent. In addition, even at moderate ultrasound pressures, microbubble oscillations
may be highly nonlinear, and the resulting harmonic content in the radiated signal can be used
to achieve even higher contrast to tissue ratios.7–9
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Beyond their diagnostic applications, microbubble oscillations have also been shown to
enhance the transport and uptake of drugs at both the tissue and cellular levels.10,11 This has
led to research across a very broad range of therapeutic applications in which focused ultra-
sound can be used to locally induce so-called “sonoporation,” leading to spatiotemporally con-
trolled drug and gene delivery. To further improve treatment localization, methods for conjugat-
ing drugs and other therapeutic molecules to microbubbles have also been developed. This
restricts the release of the drugs to the ultrasound focal zone, thereby increasing the chance that
they are taken up in sonoporated areas12 and in these areas only. Microbubbles thus offer con-
siderable promise as a means of improving the therapeutic efficiency, as well as decreasing
toxicity in healthy tissue, which is of particular interest for chemotherapeutics. Another exciting
application is microbubble-mediated drug delivery across the usually impermeable blood-brain
barrier (BBB).13 In addition, microbubbles have also shown potential in immunotherapy: gene-
loaded microbubbles have been used to transfect dendritic cells with tumor antigen encoding
mRNA to stimulate the immune system and eventually induce an efficient and long-lasting can-
cer immune response.14 Finally, more complex and indirect methods are also being investigated
for the enhanced intracellular delivery of plasmonic nanoparticles through microbubble actua-
tion to increase photothermal therapy.15
Despite some very positive results from animal studies and even preliminary clinical evalu-
ation, the mechanisms underlying microbubble-cell interactions, treatment protocols, and the
potential for harmful bioeffects remain poorly defined. Detailed investigation of the fundamen-
tal biophysical processes is thus urgently required in order to understand and quantify potential
adverse effects on cells and eventually develop efficient protocols to maximize the future
impact of the technology in the clinic. Microbubble-cell interactions have been widely investi-
gated in vitro, as evidenced by the extensive literature on this topic, and using the wide range
of techniques discussed in this paper. A major challenge is the range of timescales and length
scales over which the relevant phenomena occur. For example, microbubble dynamics occur on
the tens of nanoseconds to microsecond timescale and on the sub-micrometer to micrometer
length scale. Drug diffusion and uptake occurs on the second to minute timescale and over dis-
tances ranging from tens of micrometres (tissue level) to nanometres across the cell membrane.
The mechanical response of the cell will occur on the same timescales and length scales, as the
microbubble dynamics but the subsequent biological effects may extend over hours and
throughout a significant volume of tissue. Both this multiscale problem and the extremely large
parameter space (physical, chemical, and biological) preclude complete simultaneous control
and visualization within a single experiment. Thus, it is necessary to combine the information
gathered from multiple techniques during a single experiment.
The aim of this paper is to review the current experimental techniques that have been
applied for the in vitro study of specific aspects of bubble-cell interactions. First, an overview
of the available cell models is presented, from individual cells to 3D cellular models, and their
advantages and disadvantages discussed. This is followed by a review of the different types of
microbubbles and related agents that are currently under investigation for therapeutic applica-
tions. Finally, the instrumentation and measurement techniques available for studying
microbubble-cell interactions are examined and discussed.
II. CHOICE OF THE CELL MODEL
A. Choosing the cell type
A first essential aspect when designing in vitro studies for bubble-cell interactions consists
of selecting relevant cell types and cellular models, a choice which is directly motivated by the
targeted research question or the ultimate goal of the study. For (bio)medical applications of
microbubbles, both bacteria and mammalian cells can be of interest. The majority of in vitro
studies is conducted on mammalian cells, since those are the most relevant for applications
such as sonoporation for both gene transfection and drug delivery, as well as for imaging pur-
poses. Bacteria are mostly employed in cleaning applications16 and biofilm removal,17,18 as dis-
cussed at the end of this section.
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Fundamental studies can, for instance, be conducted on large and easy to manipulate cells
such as Xenopus oocytes19 for primary proof-of-principle experiments. Alternatively, any cell
type (mammalian cell, bacteria, or yeast cell) can be employed for the same purpose of gaining
mechanistic information on microbubble-cell interactions at the single cell level. For this purpose,
endothelial cells represent the preferred cell type.20,21 They are lining the blood vessels in which
microbubbles are injected and therefore constitute the primary targets for both imaging and drug
delivery applications. However, the most widely used cell type for microbubble-based drug deliv-
ery studies consist of cancer cell lines. Therapeutic applications of microbubbles mostly involve
tumorous tissue and cancer cells. Cancer cells are easy to culture and to manipulate and therefore
useful for fundamental studies. Finally, dendritic cells14 or lymphocytes22 are also interesting tar-
gets, e.g., for immunotherapy, since these can be reached directly from the blood stream or from
the lymphatic nodes after subcutaneous injection and drainage of the microbubbles.
Various cellular models with increasing levels of complexity are available for in vitro
experiments, ranging from individual cells and monolayers to complex 3D cellular architectures
and organ-on-a-chip platforms. While simple models are particularly interesting to gain funda-
mental insights into the cell-microbubble interactions, more complex models are closer to the
in vivo scenario, so that they provide more physiologically relevant information (Fig. 1).
FIG. 1. Diverse cell models can be chosen depending on the desired level of complexity and type of information. (A) Models
involving the study of single cells for obtaining mechanistic information. Single cells can be adherent (a, reprinted with permis-
sion from Fan et al., J. Controlled Release 170, 401 (2013). Copyright 2013 Elsevier), trapped in microfluidic structures (b,
reprinted with permission from Li et al., Lab Chip 13, 1144 (2013). Copyright 2013 The Royal Society of Chemistry) and mam-
malian or not (Xenopus oocyte in c, reprinted with permission from Zhou et al., J. Controlled Release 157, 103 (2012).
Copyright 2012 Elsevier). (B) More complete models make use of cell population that can be arranged as a monolayer (a,
reprinted with permission from Sridhar et al., PLoS One 9, e93618 (2014). Copyright 2014 Author(s), licensed under a Creative
Commons Attribution 4.0 License.79) or be in suspension (b, reprinted with permission from Tandiono et al., Lab Chip 12, 780
(2012). Copyright 2012 The Royal Society of Chemistry) in order to learn about the cell behavior in a collaborative context. (C)
More complex bottom-up models are developed in which the cells are placed in a 3D environment, that is more similar to the
in vivo situation. These models can be classified in 3 main categories: cell clusters (a), organs-on-a-chip with fully developed
blood vessels (b, reprinted with permission from Moya et al., Tissue Eng., Part C 19, 730 (2013). Copyright 2013 Mary Ann
Liebert, Inc. publishers), and biofilms (c, reprinted with permission from D. J. Stickler, Nat. Clin. Pract. Urol. 5, 598 (2008).
Copyright 2008 Macmillan Publishers Ltd.80), which are particularly used to optimize cleaning processes. (D) Some ex vivomod-
els were also used to study bubble-cell interactions such as excised tissues (a, reprinted with permission from Chen et al., Appl.
Phys. Lett. 101, 163704 (2012). Copyright 2012 AIP Publishing LLC) or a chicken egg embryo (b, reprinted with permission
from Faez et al., Ultrasound Med. Biol. 38, 1608 (2015). Copyright 2015 Elsevier) to which regulatory restrictions do not apply.
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B. Single cell models
Studying interactions between a single microbubble and a single cell yields focused infor-
mation on the impact of the microbubble on the cell, as well as on the fate of the latter. Large
cells such as Xenopus oocytes have been employed as single cell models to study, for instance,
cavitation-induced cell poration and to correlate cell-bubble distance with pore size and cyto-
plasm leakage.19,23 Recent developments in the field of microfluidics have greatly benefited sin-
gle cell experimentation,24 since microfluidic devices enable the isolation and trapping of indi-
vidual cells, e.g., with the help of dedicated micrometer-sized structures. This capability not
only enables the fate of individual cells to be tracked over a long period of time but it also pro-
vides precise control over the cell-bubble distance,25,26 a key-parameter in such bubble interac-
tion studies.27,28
Next to these mechanistic studies on cell membrane poration, other promising applications
of single cell-cavitation bubble combinations include single cell lysis before single cell analy-
sis,29 and assessment of the mechanical properties of cells30 and of the rheological properties of
their membranes.31 Cavitation-induced cell lysis is particularly advantageous from a timescale
point of view to get a precise snapshot of the content of a cell.32 Furthermore, the cell content
remains at the same location,33 which prevents any loss of molecular information. When
coupled to capillary electrophoresis for on-line separation and analysis of the cellular content,
this cell lysis protocol has brought valuable information on targeted intracellular signaling path-
ways and the activity of specific kinases.34,35 Cavitation-induced cell lysis has also more
recently been implemented in a microfluidic format33 and combined with capillary electrophore-
sis in a flow-through device for high-throughput analysis of individual cells.36 Cell mechanical
properties have been probed using microbubbles and a so-called acoustic tweezer cytometer.30
Specifically, microbubbles attached to the membrane of an individual cell were manipulated by
acoustic radiation force, and the resulting cell response subsequently recorded using an array of
PDMS (Polydimethylsiloxane) posts on which the cell was immobilized. In an alternative
approach, RBCs were exposed in a microfluidic channel to a cavitation bubble created by a
laser pulse, and their deformability recorded using high-speed imaging.31 This approach, which
was tested here on RBCs, with or without chemical treatment to alter their membrane proper-
ties, shows great promise for the characterization of the membrane properties of cancer cells
which are known to be stiffer than their healthy counterparts.
C. Cell populations: Monolayer models and suspended cells
Interactions between bubbles and cells can also be studied at the level of a cell population,
using either monolayers of adherent cells grown in conventional culture dishes or cell suspen-
sions. Cell monolayers are routinely prepared on a multitude of commercially available dish-
ware such as well-plates, OpticellsTM, or Petri dishes, or alternatively in microchannels for
experiments under flow conditions, which explains why this configuration is mostly found in
the literature for sonoporation studies.37–40 When exposed to a single jetting cavitation bubble
for drug delivery, cell monolayers have provided valuable information on the influence of the
distance between the bubble and the substrate on which cells are grown on the amount of cell
detachment, the efficiency of molecular delivery in cells, and the cell viability.20,38 Using the
same monolayer model, enhanced gene transfection has been reported more recently for human
B-cell lines using plasmid-coated microbubbles, which were activated by ultrasound.41
Monolayers formed from endothelial cells can act as artificial blood vessels, and implementing
them in a microchannel format allows studying flow-based delivery of microbubbles and reca-
pitulating physiologically relevant cellular shear stress, as would occur in vivo.42 Alternatively,
cell population studies rely on the use of suspended cells. A major limitation encountered in
this case is that suspension cells freely move with the bubble-induced flow in bulk, which pre-
vents controlled cell exposure to the bubble and from cell tracking over time. This issue has
been addressed by restricting the cell suspension in a shallow microfluidic chamber.43
Interestingly, in this confined setting, the bubble-induced flow is mostly planar and was found
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to have greater effect on cells, this effect being cell-bubble distance dependent. More recently,
Tandiono et al. applied the same approach to lyse populations of E. coli (Escherichia Coli) and
P. pastoris (Pichia Pastoris) bacteria, confirming the potential of oscillating cavitation bubbles
for efficient, fast, and contamination-free lysis of cells, without damaging biomolecules.44
Single cell and cell population models suffer, however, from serious limitations, not only
with respect to the bubble dynamics but also from a biological point of view. First, the presence
of a substrate even if it is acoustically transparent is known to strongly influence the dynamics
of the microbubbles.27,45
So, while these models allow studying bubble-cell interactions in a highly controlled way
and have succeeded in bringing insight into bubble-cell interaction mechanisms, the microbub-
ble response to the ultrasound field in these in vitro conditions is not necessarily indicative of
that which would occur in vivo. Next to this, single cells and cell monolayers are over-
simplified cellular models and are not therefore physiologically relevant. In vivo, cells experi-
ence a 3D environment with 3D interactions with neighboring cells, and they are embedded in
an extracellular matrix (ECM). As a result, cells cultured under isolated or 2D conditions
exhibit differences in their gene and protein expression profiles, as well as in their phenotype
and shape.46 Specific differences were found in the expression of cytoskeleton proteins, cell
adhesion proteins, and extracellular matrix, in processes such as proliferation and apoptosis,
and most importantly, in metabolic processes. This change in phenotype between 2D and 3D
was found to correlate with differences in the cell response to therapeutic treatments, which
highlights the need to go 3D for drug delivery and efficiency assays.
D. More complex cellular models: Toward mimicking the in vivo conditions
The scientific community is becoming more and more aware of the limitations presented
by monolayer models and is recognizing the physiological relevance of complex models that
reproduce more faithfully the 3D architecture found in vivo. Three-dimensional cellular systems
are, in particular, good models for avascular tumors which comprise a hypoxic and/or necrotic
core, and to study drug penetration and delivery in tumors.47 Such 3D cellular systems are
therefore of utmost importance for the study of microbubble-based drug delivery, where thera-
peutic agents must penetrate into tumor tissues, that consist of a combination of tumor cells,
stromal cells, and ECM.48 Furthermore, such sophisticated and 3D in vitro models appear as
attractive alternatives to animal experimentation, which is extremely expensive and time-
consuming, while requiring dedicated facilities as well as specific authorization. These complex
and 3D cellular models can be classified into three categories, which are discussed in the fol-
lowing paragraphs: artificial cellular aggregates combined with, or without, ECM, excised tis-
sues, and organ-on-a-chip platforms.
A first and fairly simple 3D model consists of a cellular aggregate, which can be prepared
from tumor cells only, or from a combination of different cell types (e.g., tumor cells and stro-
mal cells). These cellular aggregates or so-called spheroids can be produced using a variety of
techniques such as the hanging drop approach, centrifugation-based techniques,49 or alterna-
tively using microfabricated50 and microfluidic structures51 or even ultrasonic standing waves,52
to control the microtissue size and their size distribution. To produce tissue models, cells can
also be mixed with hydrogels, which serve as a surrogate for the ECM and as a “carrier” for
growth factors, while presenting mechanical properties similar to those of native tissue.
Alternatively, excised tissues can be employed as 3D cellular models, and this approach
has actually already been used in combination with bubbles. For instance, Hossein et al.53 and
Chen et al.54 have tested the effect of oscillating cavitation bubbles in capillaries on excised rat
tissues. While this model is fairly easy to use and it exhibits the exact architecture of native tis-
sue, reproducibility becomes an issue, and in addition, such experiments require sacrificing ani-
mals. Chicken egg embryos which include a vasculature with pulsating flows and for which no
authorization is required solve some of these issues.55 However, the latter model is complex to
use from an experimental point of view with the injection presenting a particular difficulty.
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The last class of in vitro complex models includes organ-on-a-chip platforms.56 These can
be defined as hybrid models combining cells and microfabricated structures, aiming at repro-
ducing the physical architecture and cell interactions found in a specific organ. These models
are implemented in a microfluidic format, which provides excellent control over the cell micro-
environment, while being ideally suited for multiplexed and automated experiments. More
importantly, and compared to cellular models alone, they allow the implementation of physio-
logical flow conditions, and they have become an attractive format to create in vitro models of
barriers57 (e.g., blood-brain barrier, kidney, intestinal barrier, blood-alveolar barriers, etc.).
Organ-on-a-chip platforms are attracting more and more attention for drug screening and toxic-
ity assays and as alternatives to animal experimentation. In a recent review, van Duinen et al.58
mentioned that 87 publications have been reporting organ-on-a-chip platforms since 2012. Of
particular interest for microbubble-related studies are vessel-on-a-chip,59 tumor-on-a-chip,60 and
barrier models, such as the BBB on a chip.61,62
Microbubbles in vivo are delivered through the blood circulation, and the first barrier they
encounter and must cross and/or damage for targeted delivery of imaging or therapeutic agents
is the endothelial barrier. A great variety of models for blood vessels have been reported in the
literature, since the latter represent an essential element of in vitro engineered tissues for proper
and selective delivery of nutrients and oxygen. One particular approach to create in vitro mod-
els of blood vessels is worth mentioning for microbubble-related medical applications, since it
consists of embedding a functional vascular network in a hydrogel ECM-like matrix, which can
act as the surrounding tissue.63 This approach would allow not only the study of the microbub-
ble delivery under physiological flow conditions followed by the rupture of the barrier upon
bubble excitation, but also the visualization of the actual release of drugs and the assessment of
its penetration into the tissue. Moya et al.64 reported the spontaneous formation of such a com-
plex vasculature in a fibrin matrix. Alternatively, blood vessels were created in channels, which
were pre-patterned in a collagen substrate and in which endothelial cells were seeded to yield a
functional vasculature.65 In this approach, the integrity of the vascular network is typically eval-
uated using a leakage assay and fluorescent dextran particles. Interestingly, the same approach
would allow the assessment of the opening of the endothelial barrier through the release of fluo-
rescent particles in the hydrogel substrate. Furthermore, the continuous ECM-like phase around
the vascular network can easily be supplemented with tumor cells66 or tumor spheroids67 for
combined drug efficiency assays.
A highly promising application of microbubbles concerns drug delivery to the brain, which
is protected by the so-called BBB, that consists of a densely packed structure formed from en-
dothelial cells on one side, and pericytes and astrocytes on the other side. The BBB prevents
the passage of substances larger than small nutrients from the blood. This selective permeability
becomes an issue when therapeutic agents must be delivered to the brain to treat diseases.
Recent work68,69 has shown that microbubbles upon ultrasound triggering actually allow local
and temporal opening of this barrier. The mechanisms of BBB permeation are however not
entirely understood, calling about for relevant in vitro models to study cell-microbubble interac-
tions and to monitor variations in the barrier permeability. Recently reported BBB models are
of prime interest, since they can reproduce the cellular structure of this biological barrier,
including flow on the blood side.61,62
Interestingly, while these more sophisticated three-dimensional models offer exciting possi-
bilities for studying in vitro microbubble-based imaging and drug delivery under in vivo-like
conditions, their utilization in combination with microbubbles and cavitation bubbles has been
limited so far to excised tissues, for which only a few references are found. This trend could
first be accounted for by the fact that these 3D models have recently gained in popularity in the
fields of biology and drug screening, where cellular monolayers are still predominant.
Furthermore, the field of organ-on-a-chip is still at its infancy, since this concept was intro-
duced in the last decade and does not yet compete with in vivo techniques such as intravital
microscopy in terms of biological relevance.70,71 However, since these complex and physiologi-
cally relevant models are becoming mature, as evidenced by the existence of commercially
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available platforms,72–74 they are likely to be adopted for microbubble-based medical applica-
tions in the very near future.
E. Biofilms
A different class of applications of (micro)bubbles, related to the medical field, focuses on
cleaning and removal of bacterial contamination and biofilms. Biofilms,16,75 which consist of a
complex 3D structure allying bacteria, substances secreted by the latter and exogenous proteins
coming from the host environment, are found, for instance, on implants and prostheses, in the
mouth in the form of dental plaque76 and in the root canals,77 or on medical devices. Simply
through their impact on surfaces, bubbles which flow in the vicinity of a biofilm have proven to
efficiently remove bacterial contamination. Parini and Pitt76 showed that cleaning of 40–lm
thick Streptococcus mutans biofilms, used as models for dental plaque, depended on the bubble
streaming velocity, the bubble size, and the gas fraction.76 In more recent work, enhanced
cleaning and deeper cleaning penetration were achieved in a root canal model in which a
Faecalis biofilm was grown for 7 days, when exposing a microbubble suspension to ultrasonic
agitation, most probably through stronger microbubble oscillation (Fig. 1).78
III. MICROBUBBLE TYPES
In the present section, we review the different types of microbubbles that have been used
in combination with the aforementioned cell models in order to study bubble-cell interactions.
In brief, microbubbles can be used to exert a stress on the cells, either in a direct way by pal-
pating the membrane during its oscillations, by stretching the membrane locally during inertial
growth and collapse, or by normal stresses through acoustic radiation forces. Microbubbles can




One of the first commercial contrast agents, Albunex
VR
(Mallinckrodt Inc., Hazelwood, MO,
USA) consisted of air microbubbles coated with a thin stabilizing layer of cross-linked human
serum albumin. Its development stemmed from the observation that the relatively short-lived
contrast enhancement that could be achieved with agitated saline could be extended through the
addition of a small amount of a patient’s blood.82,83 While Albunex microbubbles were stable
in comparison to uncoated bubbles, they were not yet able to provide a sufficiently long con-
trast enhancement in vivo, and new agents containing higher-molecular-weight gases were con-
sequently developed. OptisonTM (GE Healthcare Inc., Princeton, NJ, USA), for example, con-
tains perfluoropropane with a high molecular weight (MW¼ 188 g/mol) in order to decrease the
diffusivity of the gas across the bubble wall and the solubility in the surrounding liquid. All of
the clinical agents currently in use contain gases of this type, although Kwan and Borden84
have shown that even these heavy gases are actually replaced by dissolved blood gasses (mostly
N2 and O2) within a few minutes. The improvement in stability is therefore relatively modest.
These microbubbles, being a few micrometers in diameter, show limited circulation time in the
blood stream. As a consequence, such bubbles interact in the first place with blood cells, which
currently attract interest for the targeting of immune cells.85,86 However, most studies using sta-
bilized microbubbles are performed with tumor cells. It must be borne in mind that these micro-
bubbles cannot directly reach these cells, which are located beyond the vascular barrier.
Studying the interactions with endothelial cells, however, becomes more and more relevant as
the size of the vessels reduces upon nearing the capillary bed, favoring the interaction of the
bubbles with the vessel walls. Identifying the type of bubble-cell interactions is crucial for
enhancing the permeability of the vessel walls in order to locally improve drug uptake by the
interstitial tissue as well as for quantifying the deleterious effects of oscillating microbubbles
and the risk of permanent damage. This can be studied best with cell membrane models and
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3D complex models that comprise an endothelial cell layer. In more specific cases, such as
immunotherapy, immune cells in the blood pool or lymphatic circulation can be a direct target
for the microbubbles, which can be studied in an in vitro set-up with direct contact between
microbubbles and target cells for fundamental aspects, i.e., single fixed cells, or in a suspension
of cells, representative of a blood pool.
To improve convenience of administration, many of the second generation contrast agents
were packaged as freeze-dried powders that could be stored and resuspended in saline as
required, rather than being prepared immediately prior to injection. Alternative means of admin-





(Schering AG, Berlin, Germany), consisted of suspensions of galactose micro-
crystals, which dissolved in the blood following injection, releasing air microbubbles from
defects on the crystal surfaces. Levovist also contained palmitic acid to provide additional sta-
bility. Levovist microbubbles were found to be more echogenic than Albunex, but considerably
less stable on account of the higher diffusivity of their surfactant coatings. Hence, Levovist was
soon superseded by agents containing bubbles stabilized by phospholipid monolayers that pro-




(Bristol-Myers Squibb Medical Imaging Inc., USA), and
SonazoidTM (GE Healthcare Inc., Princeton, NJ, USA). Even greater microbubble stability can
be afforded by the use of polymeric coatings (e.g., polylactic(co)glycolic acids, polycaprolac-
tone, or cyanoacrylates).87–91 In selecting the optimum coating material, however, there is a
tradeoff between stability and echogenicity and particularly non-linear behavior that is desirable
for contrast enhancement.92,93
The majority of microbubble agents used for both for clinical applications and for research
purposes are produced by conventional emulsification methods, and most often using a combi-
nation of sonication and physical agitation. These methods are efficient and convenient but
yield highly polydisperse microbubble size distributions.94 Alternative methods including micro-
fluidics95 and electrospraying96 have been investigated, but systems offering competitive pro-
duction rates and/or microbubble stability are still under development. Feshitan et al.97 have
demonstrated that improvements in the contrast to tissue ratio can be achieved through filtering
microbubble suspensions to match their size distribution for a given imaging protocol. Segers
and Versluis98 have also recently demonstrated that microbubbles can be sorted according to
their acoustic properties similarly offering a significant improvement in imaging performance.
Although this smaller size distribution should not influence the circulation time of the micro-
bubbles, it is expected to allow better control over microbubble cavitation behavior, and thus
on the mechanical and therapeutic impact on the surrounding cells. The absence of larger
microbubbles in the batch might, for instance, reduce the amount of undesired effects caused
by cavitation.
2. Functionalized and drug-loaded microbubbles
Tissue specificity, e.g., for targeted imaging and therapy, requires functionalization of the
microbubble surface (Fig. 2.B). Microbubbles coated with charged material have been shown to
locate preferentially in inflamed tissue,99 but a more effective method consists in attaching ligands
to the bubble surface that will bind to receptors on particular types of cell.100 Examples include tar-
geting to activated leucocytes by incorporating phosphatidylserine in the microbubble coating;101
angiogenic markers;102 and attaching antibodies to microbubbles targeted to receptors expressed
during inflammation (e.g., anti-P-selectin monoclonal antibody, anti-NICAM antibody, and anti-
VCAM antibody).103,104 The target here can probably be tumor endothelial markers or neovascular
markers on the tumor vessel endothelium. Such systems are most often represented in vitro by cell
monolayers, although future research would greatly benefit from the use of organ on chip platforms.
These bubbles also present great interest for use in cells suspensions, e.g., for targeting circulating
tumor cells (CTCs) with high precision105,106 or to quantify the binding efficiency with white blood
cells in a vessel. An alternative method for localizing microbubbles in vivo is to load them with mag-
netic nanoparticles. This enables the microbubbles to be guided into the target region using an
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externally applied magnetic field107 either as an alternative to biochemical targeting or as a means
of slowing the microbubbles down sufficiently to facilitate binding.
Surface functionalization can also be exploited for attaching therapeutic components to
microbubbles.108,109 Recently developed loading strategies include self-assembly methods for
the production of liposome-loaded microbubbles.110 These offer considerable advantages in
terms of simplicity and the quantity of drug that can be attached to a single bubble, although it
has been shown that the additional loading does modify the microbubble dynamics.111
Nevertheless, such bubbles have been shown to be highly effective in delivering cytotoxic
drugs, although the underlying mechanisms still require significant investigation.112 The same
method combined with specific binding strategies has also been used to load fluorescent dyes
into liposomes attached to phospholipid-coated microbubbles in order to study their dynamic
behavior.111 A dye can also be inserted directly within the coating.113 These formulations are
most useful to investigate release and uptake mechanisms upon ultrasound exposure.
If contrast enhancement is not the primary consideration, then polymer-coated microbub-
bles can offer several advantages for drug encapsulation thanks, in particular, to the relative
ease with which their size, shell thickness, and drug loading can be controlled.91,114–116
Polymer coatings can also be readily functionalized for molecular targeting.117 The acoustic
response of polymeric microbubbles is typically very different from that of a phospholipid-
coated microbubble, with negligible volume oscillations followed by rupture of the coating
above a threshold acoustic pressure.115,118 The dynamics of the released gas may be compara-
tively violent, and hence the interactions between polymeric bubbles and cells also require
detailed investigation.
3. Echogenic liposomes
Echogenic liposomes are an alternative type of acoustically active drug carrying particle.
They are in fact very similar to microbubbles in terms of their composition119 but consist of a
multilamellar phospholipid structure entrapping pockets of gas, which also offers the potential
for encapsulating both hydrophobic and hydrophilic material.120 They have been shown to offer
improved stability compared to microbubbles.121 Larger doses of echogenic liposomes (i.e., par-
ticles per unit volume) are required to obtain equivalent levels of contrast enhancement during
imaging, on account of their lower gas content per particle, but such high concentrations are
well tolerated physiologically.122 Similarly, specific pulse regimes are required to initiate drug
release.123
4. Light absorbing microbubbles
A further recent development concerns laser-activated microbubbles. The bubble coating
can be loaded with light-absorbing particles (Fig. 2.B.c)124 or a low-viscosity oil containing
an absorbing dye.125 Upon exposure to laser light, the heating and subsequent expansion of
the coating sets the microbubble into volume oscillation, thereby generating similar acoustic
and fluid dynamical effects as ultrasound exposure. These bubbles have the potential to be
used for other imaging modalities such as photoacoustic imaging.126 A usual difficulty
encountered with laser-based medical imaging techniques such as photoacoustics lies in the
limited penetration depth of the laser light combined with the high degree of tissue scattering.
Such complications are, however, highly reduced in in vitro models. A typical cell layer
thickness of a millimeter, for example, transmits almost 80% of the near-infrared light inten-
sity. The increased specificity of laser light, however, justifies its use in a number of superfi-
cial pathologies located in just below the skin, e.g., skin cancers, esophageal cancer, or rheu-
matoid arthritis in finger joints.
B. Droplets as precursors
Another approach to producing microbubbles utilizes a stabilized emulsion of volatile liq-
uid droplets (Fig. 2.A.a), which vaporize to form microbubbles upon injection into the body or
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subsequently to exposure to ultrasound. The fluids commonly chosen are octafluoropropane,
decafluorobutane, or dodecafluoropentane127 that have boiling points of 37 C, 4 C, and
29 C, respectively. These boiling points are lower than normal body temperature, so that these
fluids become superheated in vivo. These perfluorinated liquids present a number of advantages:
first, they have a tunable boiling point depending on the carbon chain length that falls precisely
in the range that is relevant for medical applications. As for stable microbubbles, the droplets
are surfactant-coated to ensure higher stability and better shielding against the immune system
and to spontaneous vaporization. Second, these perfluorocarbons are already in clinical use for
a number of other applications (including ultrasound contrast agents). Third, this type of agent
exhibits improved stability both for storage and administration and, unlike microbubbles, the
nanoscale droplets have the potential to extravasate, e.g., through leaky tumor vasculature,
before they are vaporized. This facilitates imaging and/or treatment, e.g., within a tumor
mass.127,128
The interest of using such precursors lies in the injection in the bloodstream of a nanosized
agent that is able to extravasate through large pores as typically found in tumor blood vessels
(EPR (enhanced permeability and retention) effect129). Upon vaporization, the resulting micron-
sized bubbles can interact with the deeper-lying tissue. In this regard, the collection of mecha-
nistic information on the interaction of stable bubbles with single cells or cell monolayers is
most valuable. The dynamics of the penetration process of the precursor, however, can best be
studied in vitro using 3D blood vessels or organ-on-a-chip models.
Whilst recent studies have advanced our understanding of the physics of superheated drop-
lets under ultrasound exposure130 extremely little is known about their interactions with cells
before, during, and after vaporization. Interestingly, the bubbles generated from superheated
droplets exhibit characteristics similar to those of phospholipid-coated bubbles. This implies
that the surfactant initially stabilizing the droplet can also stabilize the bubble and support non-
linear oscillations.131 Perfluorocarbon droplets also offer the potential to be used as multi-
modality agents, since they can be activated using ultrasound127,130,131 but also using light
when internally loaded with plasmonic nanoparticles,132 which leads to an increase in photoa-
coustic contrast and the creation of a ultrasound microbubble contrast agent simultaneously.
C. Solid particles as microbubble nuclei
Notwithstanding the improvements in microbubble stability that can be achieved through
selection of appropriate materials and/or surface functionalization, they still offer very limited
circulation times. As discussed before, superheated nanodroplets130,133 offer a solution to this
problem. Another approach consists in the use of solid functionalized particles on the very
same cell models. Here, their surface properties and morphology enable them to act as nuclei
for bubble formation.
1. Acoustically responsive particles
As mentioned above, polymeric coatings can significantly enhance microbubble stability,
albeit at the cost of echogenicity. Nanoscale polymeric particles can also be produced using stand-
ard emulsion and solvent evaporation methods,134 and they either encapsulate a gas core135 or con-
sist of a gas entrapping porous matrix (Fig. 2.A.c).136 Such particles offer excellent stability even
under high-intensity ultrasound exposure and have been shown to sustain cavitation over signifi-
cantly longer periods than microbubbles. Other systems have also been reported in the literature
such as the hydrolyzing, gas-generating nanoparticles by Kang et al.,137 able to create bubbles
over timescales of several minutes, or carbon nanotubes as ultrasound contrast agents.138
Describing all of these systems, however, would be beyond the scope of this review.
2. Light responsive particles
Just as a drug can be encapsulated within a polymeric particle, so too can a dye that makes
the particle light-absorbing (Fig. 2.A.b). Upon irradiation with light of sufficient intensity, such
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particles can generate bubbles that radiate strong acoustic emissions enabling them to be
detected.139 The majority of the research on light-activated bubbles however has made use of
plasmonic nanoparticles such as gold nanospheres (AuNS) or nanorods (AuNR). More complex
nanoparticles such as gold-coated beads140 have also been investigated for the generation of
plasmonic bubbles. Plasmonic nanoparticles have a unique light absorption cross section with
respect to their size at the specific wavelength of the plasmon, which itself corresponds to the
motion of the electron cloud of the particle. AuNS and AuNR have been used for some years
in classical thermoelastic photoacoustics but their capacity for transient microbubble generation
has only recently been investigated.132 Although these particles have been used in pre-clinical
imaging and/or for inducing hyperthermia, the question of their short and long term toxicity
remains unclear. So far, preliminary investigations of the interaction between cells and optically
generated bubbles have been reported by Lukianova-Hleb et al.141 but further, more detailed
studies are required.
D. Agent behavior and tissue type
Literature related to microbubble-cell interactions focuses on how bubbles act on cells and
tissues, and this idea reflects on the organization of Secs. I and II of this review. However, very
little is known on how the various tissue types influence the agents as most experiments are
simply performed in aqueous fluids. As mentioned before, both the presence of a boundary and
the viscosity of the fluid142 are known to have a major effect on the microbubble behavior;
therefore, the viscoelastic properties of human tissues can be expected to change the response
of the agents to ultrasound in terms of activation threshold, as well as its resonance frequency
and amplitude response. This aspect, often forgotten, is nonetheless a crucial part of the intri-
cate problem of bubble-cell interactions. Some very recent numerical work, e.g., that by
Gaudron et al.143 and Johnsen and Mancia144 has pioneered microbubble dynamics in a visco-
elastic medium. Clearly, more work needs to be done on the topic, in particular, from an exper-
imental point of view, as any smaller number of dimensions than a 3D cell model would fail to
reproduce the relevance of the environment. Within the range of available 3D models, the sim-
plest ones, e.g., spheroids, can provide a more fundamental understanding of the effect of the size
and type of constructs formed by the cell population. However, different tissues are also known
to have different viscoelastic properties,145 one that is exploited in shear rate imaging of tumors,
for example. Therefore, studying experimentally the complex two-way coupled problem of agent
penetration/activation/forcing on cells requires a well-defined 3D structure that includes the inte-
grative behavior of various cell types and viscous flow, which can be provided by microtissues
and organ-on-a-chip models. More advanced 3D models can also add more intricate modifications
such as the biochemical activity of the tumor, thereby creating a different tumor micro-
environment that induces a higher chemoresistance and, more in general, different cell
response.146 Such effects are of prime interest when using bubbles as the local carriers (Fig. 2).
IV. EXPERIMENTAL METHODS
A. Excitation of the microbubbles
1. Optical excitation
Section III has shown that microbubble dynamics may be both excited and interrogated
optically and/or acoustically. In terms of optical excitation, current technology already offers
pulsed and continuous wave (CW) lasers that provide full control over wavelength, power, and
energy distribution in space and time. Therefore and despite the experimental hazards associ-
ated with them, lasers are the most suitable light sources for studying the interaction of opti-
cally activated or driven microbubbles and cells. Their safe use is already warranted below a
medical guidelines threshold that depends on both the duration of the irradiation and the wave-
length of the laser light (20mJ/cm2 at 532 nm and 60mJ/cm2 at 1064 nm for nanosecond pulsed
lasers). These exposure thresholds are directly related to the energy deposited in tissue through
light absorption. As mentioned previously, sufficient optical excitation in vivo under this
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threshold can be difficult for larger penetration depths. Although this limitation is hardly an
issue for in vitro models, since even the 3D models have a typical thickness of only a milli-
meter, it emphasizes the need for highly efficient agents to increase both contrast and imaging
depth. Laser light with a 1064 nm wavelength is located right in the biological window,147 i.e.,
with highest tissue transparency, and thus is less damaging to tissue. In practice, however, a
laser operating in the visible range at a wavelength of 532 nm is easier and safer to use. The ex-
citation wavelength of many known absorbers, such as the plasmon resonance of gold nano-
spheres, is also located near 532 nm. The best choice for the wavelength will therefore also
depend on the stage of development of the considered agent. Practically, if the bubbles
are equipped with the right fluorophores, light can be used to directly impact on the bubbles.
FIG. 2. Schematic representation of microbubbles precursors (A) and functionalized microbubbles (B). (A) Superheated,
liquid perfluorocarbon nanodroplets are stabilized by a surfactant layer and can be vaporized with ultrasound or laser pulses
(a); fluorescently labeled nanoparticles can generate microbubbles when exposed to laser light (b); and polymeric nanopar-
ticles encapsulating a small gas core can be used as sustainable microbubble precursors (c). (B) Microbubbles can be func-
tionalized by attaching targeting ligands (a); loading them with drug-containing nanoparticles (b) or make them suitable for
multimodal imaging by covering them with plasmonic nanoparticles (c).
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The expansion of the gas core then occurs through thermal effects.124,148 Thus, heat rather than
light is generating or driving the bubbles, which in turn generates or scatters the acoustic waves
for imaging purposes.
A pre-existing gas microbubble will respond to optical excitation due to thermal expan-
sion.124,149 This phenomenon has been investigated using both pulsed124 and CW lasers.149 The
former have been more commonly applied on account of their availability for photoacoustic
imaging. A much larger number of studies have used laser exposure and the subsequent heat
generation to create vapor and/or gas bubbles. A focused laser beam of sufficient intensity will
produce a plasma in water.23,43 Taking advantage of the capability to precisely control the dis-
tance between the laser focus and a single cell in a chip, Li et al.26 used an array of cell trap-
ping structures in a PDMS microchamber and found that a shorter cell-bubble distance led to
the creation of larger pores. More interestingly, the presence of a trapping structure was found
to guide the micro-jet originating from the cavitation bubble collapse towards the cell, thereby
enhancing the poration process. Light absorbing precursors, such as described in Sec. III, may
also be used to provide better spatiotemporal control over light-induced cavitation proc-
esses.132,149 Alternatively, bubbles may be produced through thermally induced vaporization of
an injected, initially liquid agent such as perfluorocarbon droplets,150 typically at lower optical
intensities.149 In most cases, the laser is directly coupled through an observation microscope
using a dichroic filter,124,139,151 allowing for an exact spatial localization of the beam and for a
selective excitation of the agents in the sample. The use of CW lasers is still at an early stage
and the intensity values reported in literature, as of now, are too high for in-vivo use. Simple
cell models such as monolayers are therefore still suitable to evaluate thermal and mechanical
damage from pulsed and CW laser-activated agents. Furthermore, laser light offers reduced in-
terference with a potential supporting membrane over ultrasound, thereby overcoming the limi-
tations of the use of monolayer models for laser-activated applications.
2. Acoustic excitation
a. Acoustic field. Whilst the experimental hazards are usually less significant, accurate spa-
tiotemporal control of an acoustic field may be considerably more challenging than its optical
counterpart. Particularly, problematic is the elimination of unwanted reflections from boundaries
within the system to avoid the disruption of the sound field incident upon the microbubbles. In
the most extreme cases where long pulses are used in combination with an objective lens, for
example, it becomes a challenge to suppress the creation of standing waves that were shown to
significantly influence the outcome of a sonoporation experiment.152 The calibration of an
acoustic field with existing technologies, using, for example, hydrophones, can be done with a
typical 10% error at best. With the inclusion of reflections within the setup, the uncertainty of
the acoustic pressure can rapidly rise above 50%. In some cases, the transducer is positioned
perpendicularly to the cell support, and the occurrence of multiple reflections and ultimately
standing waves is unavoidable.153 Hensel et al.154 have also demonstrated that the position of
the transducer with respect to the sample holders could greatly influence the acoustic field.
They concluded on the necessity to use acoustically transparent materials, e.g., a polymer pre-
senting an acoustic impedance close to that of water. Such materials, however, are not easy to
find, in particular, when considering the impact of the angle of incidence. For example, the
transmission coefficient of an Opticell membrane drops from over 99% at normal incidence to
about 85% at 45 incidence and 1MHz113 and is strongly frequency dependent. Along the same
line, Cochran and Wheatley39 observed that much lower transfection efficiencies were achieved
when microbubbles are pushed away from cells by the acoustic wave rather than pushed
towards them. This simple observation holds for any choice of cell model and is inherent to
in vivo setups. Taking these effects into consideration, optimal control over the acoustic field
will be achieved when using a focused ultrasound transducer inserted under an angle that
allows for the reflected waves to escape the region of interest. The unknown acoustic field
remains in any case an experimental difficulty to consider.
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b. Acoustic parameters. Numerous studies have reported that the choice of the acoustic pa-
rameters is crucial in achieving cell poration.81,155 When performing a bubble-cell interaction
experiment, one can vary the acoustic pressure, the frequency, the number of cycles per bursts,
the pulse repetition rate, the total duration of the experiment, and each of these parameters will
affect the outcome of the experiment. Some studies have chosen to limit the investigation to a
single parameter, usually the acoustic pressure, using short bursts156,157 in order to learn about
the precise dynamic phenomena at hand. Others have chosen to maximize the uptake using
repeated bursts of a few thousand cycles155 for a total duration of up to several minutes to
define the setting that may give the best results in vivo. In addition, the response of a range of
microbubbles and microbubble precursors presented in Sec. III, at the very same acoustic set-
ting will be entirely different.90 In order to provide an overview of the state of the art, we clas-
sify the acoustic parameters in terms of their effect upon the bubble dynamics, leading to three
main categories.
First, “stable” or non-inertial cavitation is observed when microbubbles are driven at rela-
tively low acoustic pressures. They then undergo repetitive volumetric oscillations that are only
weakly non-linear. The acoustic pressures used in that regime typically range from 10 to
150 kPa. In this regime, the acoustic emissions from the microbubble will contain some har-
monics and potentially also subharmonic and ultraharmonic components. This regime has been
shown to induce sonoporation156 usually with relatively low transfection efficiency, but with a
high cell viability.81,155
At higher acoustic pressures, inertial cavitation is observed, which is characterized by a
much more chaotic microbubble behavior. The term “inertial” is derived from the analysis by
Flynn158 and relates to the fact that the compression phase of the microbubbles is driven by the
inertia of the surrounding liquid rather than by variations in pressure. In this regime, the bubble
usually becomes non-spherical upon collapse, which may lead to micro-jetting.26 In this case,
the acoustic pressures typically range from 150 to 500 kPa, leading to stable microbubble cavi-
tation. The corresponding acoustic emissions are broadband in nature.159 Vaporization of liquid
precursors of bubble also falls in this category.131 This regime is the most reported one in the
study of bubble-cell interactions, for example: Smith et al. reported sonoporation resulting from
cavitation of echogenic liposomes,123 Zhou et al. used inertial cavitation to porate oocyte
cells,23 and Zhao et al. used cavitation to induce cell apoptosis.11 Using larger bubbles, Ohl
et al. observed two regimes of viable porated cell and detached dead cells.20 More specific
agents, such as superheated nanodroplets or similar bubble precursor nanoparticles, often
require much higher activation pressures, typically over 1MPa. As such, their subsequent bub-
ble behavior is inherently inertial.
In addition to the dynamics of the microbubbles themselves, there are a number of second
order phenomena, induced by the bubbles over a timescale longer than their own oscillations
that are likely to play a significant role in microbubble-cell interactions. Most prominent
amongst these effects are microstreaming and acoustic radiation forces. Streaming induced by
microbubbles under ultrasound irradiation is of interest for the local stress that is generated by
local fluid velocities of the order of 0.1m/s.113 Pommella et al.,160 for example, recently
achieved vesicle lysis using the microstreaming generated from a single microbubble (approxi-
mately 50 lm diameter) at low acoustic pressures. In this case, the acoustically induced micro-
streaming could generate stresses as high as 300 Pa. In the absence of cells, Vos et al.161 even
reported, based on a parametric analysis, local peak shear stresses as high as 300 kPa. Oh
et al.162 used microbubble generated streaming on tissue mimicking samples in order to
increase the perfusion distance. The same effect is investigated to improve the efficiency of clot
dissolving drugs. Others show interest in the effects of the streaming induced by contrast agents
in on-chip vessels.163 Finally, streaming is also suspected to be an important mechanism for the
delivery of drugs loaded on microbubbles.113 Moreover, exploiting the acoustic radiation force
on microbubbles that arises from the phase difference between the microbubble volumetric
oscillations and the acoustic wave164 is an important method for the manipulation of single bub-
bles, as well as an often undesired effect in vitro. Radiation force was used for the study of the
mechanical properties of cells, e.g., their resistance to shear,30 showing that a peak shear stress
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of a few Pa (corresponding to a maximum shear velocity of approximately 4mm/s) was
sufficient to induce membrane poration. Radiation force was also applied to the non-invasive
manipulation of stem cell-bubbles clusters in vitro and in an in vivo CAM (chick embryo cho-
rioallantoic membrane) model to increase their attachment to the vessel wall at the desired loca-
tion.165 These complexes could be pushed without damage at velocities up to 0.25mm/s using
a pressure of 450 kPa with an off-resonance 1MHz acoustic wave.
B. Optical imaging
1. Fluorescence imaging
a. Real-time fluorescence imaging. In order to evaluate the effect of microbubbles and ultra-
sound on drug uptake by cells, fluorescent molecules are almost exclusively used in the litera-
ture, since they are easy to use and since there is a wide variety of molecules available.
Analysis of fluorescent molecular uptake is often performed by fluorescence microscopy. The
most frequently used molecules are propidium iodide (PI),30,166,167 calcein,168–170 and SYTOX-
dyes.171–173 These are small molecules (a few nanometer in size) and can serve as model for
low molecular weight drugs. Moreover, they are cell-impermeable and can therefore act as a
marker for the creation of pores in the cell membrane generated by microbubble-cell interac-
tions. Larger fluorescent molecules such as fluorescent dextrans168,174,175 or fluorescent
spheres176,177 represent larger drugs, as, for example, nanoparticles and can be used to deter-
mine membrane pore size and to investigate the role of endocytosis.
As an alternative to the small cell-impermeable fluorescent dyes, the influx of calcium can
be measured to detect the formation of cell membrane pores. The increase of the intracellular
calcium concentration upon membrane poration can be monitored by using probes that bind to
intracellular calcium, such as Fluo-4AM169,174,178 and Fura-2AM.153,167,179
The influx of these fluorescent molecules and calcium occurs on a timescale of a few sec-
onds and can therefore be readily imaged by real time fluorescence microscopy. These dyes are
also often combined with dyes that stain live or non-viable cells after ultrasound exposure. In this
way, these fluorescent molecules are a unique tool to visualize processes occurring in, on, and
around the cell. The field of view, and similarly the depth of field, of fluorescence microscopy is
inversely proportional to the magnification and is typically a few micrometers. This technique is
therefore suitable to image typical in vitro models. The highest imaging precision, however, is
achieved on cell monolayers, since the focus in a 3D structure will extend over multiple cell
layers, making it difficult to focus on single cells. In the latter case, background noise will
increase due to out-of-focus fluorescence and contrast of the deeper layers will decrease due to
the turbidity of the tissue. As an example, Luan et al.113 could readily and quantitatively measure
fluorescence from released material that was out of focus by tens of micrometers.
b. High-speed fluorescence imaging. Fluorescence imaging can also be performed at higher
frame rates (Fig. 3.A and C). Luan et al.113 were able to monitor on the microsecond time scale
the release of model drug from fluorescently labeled microbubbles at up to a frame rate of 150
thousand frames per second, resolving the effects of the microbubble-induced streaming. High-
speed fluorescence imaging is thus beneficial for applications involving second-order effects
such as streaming or radiation force. However, high-speed fluorescence imaging cannot be used
on cells directly, as cell staining has a significantly lower intensity, i.e., membrane staining is
hardly imaged faster than at a few tens of frames per second, while PI-uptake can be imaged at
a few hundred frames per second.157
c. Confocal imaging. On the same timescales and with the same general motivations than for
real-time fluorescence imaging, confocal fluorescence microscopy is used to visualize the cell
structures, bubble coatings, and influx following ultrasound exposure.155 Using the high-
resolution capability offered by confocal microscopy, Hu et al. could visualize the dynamic
recession, or expansion, of single pores in sonoporated cells (Fig. 4.A)180 in order to understand
the mechanisms by which a cell can self-heal. Chen et al. also showed how confocal
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microscopy could be used to image disruptions in the actin cytoskeleton of the cells as a result
of their interaction with microbubbles.171 In contrast to fluorescence microscopy, confocal mi-
croscopy can also be performed in 3D. This complete spatial information on the cell allows for
the assessment of volume information in both the endothelium and the cell nucleus181 or to
observe the 3D organization of the cell. Confocal microscopy can display very thin layers (typi-
cally a few hundreds of nanometers) and can thus be used to visualize single planes in so-
called z-stacks.182 This last aspect is expected to become increasingly important with the devel-
opment of complex 3D cell model. Finally, confocal imaging of barrier models cells can pro-
vide information on bubble-induced gaps within tight-junctions, e.g., the blood-brain barrier by
monitoring the location of proteins such as ZO-1.183 Confocal microscopy is very well suited
for the imaging of the dynamic cell response180 and to quantify with remarkable detail molecu-
lar diffusion processes184–186 within the structure of single cells and cell monolayers. When
imaging thicker samples, however, as is the case for 3D cell models, the turbidity of the tissue
layers renders high-resolution confocal imaging difficult and calls upon complex image analysis
and reconstruction. With such tools, the imaging depth can be increased to beyond 1mm.187
Alternatively, thicker samples can be imaged with a significant improvement in depth by two-
photon or multiphoton microscopy188,189 or prepared post-experiment to offer better imaging
capabilities off-line (see Sec. IVD).
2. High-speed bright-field imaging
High-speed, bright field microscopy allows for the study of microbubble-cell interactions on
the timescale of the ultrasound cycle or faster (Fig. 3.B and C). In particular, the Brandaris 128
ultra-high-speed camera was designed 15 years ago as a unique tool to record at up to 25  106
frames per second190 and has been widely used to study microbubble related problems. The ability
to record at sufficiently high frame rates to resolve the ultrasound contrast microbubbles oscilla-
tion has facilitated the obtention of invaluable insight into fundamental bubble behavior.191 More
recently, recordings made with the Brandaris camera have also revealed that bubble oscillations
can result in the pulling and pushing of the cell membrane.21,192 More violent bubble behavior
such as microjetting towards the cell can also occur and be recorded by such a system, as observed
by Prentice et al.25 Ultra high-speed imaging is also the only existing method that allows for relat-
ing the details of the microbubble oscillation dynamics with the impact on the cells,21 or the
microbubble behavior to the release of drugs loaded on their surface.113 This represents a critical
aspect of the investigation of bubble-cell interactions. Other microbubbles such as plasmonic
nano-bubbles have a very short lifetime (a fraction of microsecond) and therefore can be directly
characterized only at such high frame rates. Other methods based on light scattering, for example,
can detect transient bubbles but with limited possibilities to characterize them.151
Most commercial high-speed cameras cannot record faster than a few hundred thousand frames
per second. This is insufficient to resolve microbubbles oscillations, but can prove instrumental in
learning about the events on the timescale of the ultrasound bursts, e.g., the effect of microbubble
cavitation on capillary blood vessel excised from rats.53,54 These camera systems were also used to
study the impact of larger bubbles, with a slower dynamics, on a collection of cells.38
High-speed bright-field imaging can however not bring structural information on the cells
at these times scale, which limits its relevance mostly to the observation and quantification of
the bubble behavior itself and thus requires the simultaneous use of complementary techniques
in order to extract information from the cells (Fig. 3).
C. Sensing
Aside from imaging methods, sensing techniques can be used to probe the nature of
bubble-cell interactions and their consequences. Sensing methods are important for the study of
bubble-cell interaction as they offer a direct measure of cell membranes and/or intercellular ma-
trix integrity on the timescale of the ultrasound, e.g., using electrical sensing methods.
Moreover, they give a remote feedback on the bubble activity in relation with the cell response.
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This feedback can be used later to quantify the resulting effects in vivo where the aforemen-
tioned imaging techniques cannot be used.
1. Electrical methods
a. Transepithelial electrical resistance (TEER). Bubbles have proven to be an attractive active
means to pass foreign substances, such as drugs, across physiological barriers like the BBB.
FIG. 3. (A) High-speed fluorescence imaging of the uptake of propidium iodide (PI) used as model drug by a cell as a result
of membrane poration by an oscillating microbubble.193 (B) Ultra high-speed recording (interframe time of 58 ns) of the
interaction of a vaporizing superheated microdroplet with a cell upon ultrasound exposure at 5MHz.194 (C) Combined
high-speed fluorescence imaging and bright-field ultra high-speed imaging to visualize the sonoporation of cells by short-
lived cavitation bubbles. The bubbles are created by laser activation of polymeric microcapsules.195
011501-17 Lajoinie et al. Biomicrofluidics 10, 011501 (2016)
 This article is copyrighted as indicated in the article. Reuse of AIP content is subject to the terms at: http://scitation.aip.org/termsconditions. Downloaded to  IP:
130.89.96.101 On: Thu, 28 Jan 2016 15:00:16
The permeation of barrier models following their exposure to bubbles can first be assessed by
evaluating the integrity of the barrier. A conventional approach to this end consists in meas-
uring the TEER of the barrier model,196,197 which corresponds to the electrical resistance of the
cell monolayer grown on a porous substrate/membrane (Transwell inserts, typically). Two main
approaches are reported to determine TEER values: the first one directly assesses the electrical
resistance of the cell monolayers. This principle is employed by the commercially available sys-
tems for TEER measurement (EVOM, World Precision Instruments, Sarasota, FL). The second
method is based on impedance spectroscopy, which provides additional information on the elec-
trical capacitance of the cell monolayer. When the cell monolayer reaches confluency, cells es-
tablish tight junctions with each other, and the monolayer is characterized by a high TEER
value. On the contrary, the creation of gaps between cells after bubble actuation, for instance,
is accompanied by a decrease in the resistance of the monolayer. Interestingly, the TEER can
be monitored continuously and in a non-invasive manner, yielding real-time information on the
barrier characteristics.
b. Trans-membrane current (TMC). TMC measurement is a sensing technique that measures
the electrical intensity carried by the ions that passes across the membrane of a single cell. The
technique involves a pair of electrodes, which are placed in the intracellular and extracellular
medium, respectively. This technique give real-time information on the cell membrane porosity
as the flux of ions directly relates to the number and size of the pores in the membrane. TMC
can be directly correlated to the cell pore size.23
2. Ultrasound sensing
Ultrasound was largely discussed in Sec. IVA of this review as an excitation method.
Ultrasound detection is also one of the main sensing methods and is very often used for the
detection of broadband cavitation noise159 as a measure for the energy release by the bubbles
in the vicinity of the cells. Although ultrasound sensing is typically performed with a single ele-
ment transducer with sensitivity on the order of 1 Pa, it can also be achieved with a commercial
ultrasound system in order to obtain, in addition, the spatial information of the occurring
events.198 Ultrasound is also a crucial sensing method to quantify the response of a photoacous-
tic agent132 or to obtain direct information on the physical mechanisms underlying the cavita-
tion events.139
D. Off-line techniques
Some techniques such as described hereafter cannot be performed simultaneously with the
experiment or ultrasound exposure. These methods, termed here off-line techniques, can be
used to access precise details of the cell structure after ultrasound irradiation or to obtain quan-
titative statistical information (Fig. 4).
1. Off-line confocal imaging
In the fluorescence imaging section, we mentioned the difficulties encountered in studying 3D
samples using fluorescence techniques. As an alternative, these 3D samples can be studied off-line
to yield high-resolution information on the impact of the bubbles on the tissues, e.g., in terms of
tissue damage, drug penetration, and efficiency of intracellular drug delivery. The most commonly
used approach relies on the fixation of the tissue using, for instance, paraformaldehyde followed
by the embedding of the tissue in paraffin, to then perform cryosectioning of the tissue to yield
thin slices that can readily be imaged using confocal microscopy. Another more recent and highly
promising strategy, also known as tissue clearance or CLARITY,199,200 consists of embedding the
tissue or 3D cellular constructs in an acrylamide gel matrix, followed by removal of the lipid mol-
ecules to yield a transparent 3D structure. This 3D structure is not only suitable for 3D imaging
by allowing deep optical penetration but it also facilitates the penetration of all probes required for
tissue staining, another concern encountered with the thicker 3D cellular aggregates.
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2. Electron and atomic force microscopy
Other forms of microscopy have also been used to examine single fixed cells or cell mono-
layers. These include scanning electron microscopy (SEM, Fig. 4.B),23 transmission electron
microscopy (TEM),201 and atomic force microscopy (AFM).25,202,203 Using these techniques,
the direct effects of microbubble cavitation on cell morphology and topography can be studied.
Cell size has been shown to decrease after ultrasound radiation,176 and smoother and flatter cell
surfaces have also been observed.21 Moreover, clear perforations in the cell membrane could be
imaged.25,91,166,176 The size of these pores has been estimated to be several hundred nanometres
up to a few micrometres. These techniques, however, are applied after the actual experiment in
which the bubble-cell interaction occurs. Therefore, small pores can have already resealed by
the time, the sample preparation is completed, and the sample preparation itself can also cause
artifacts in the image. Thus, these microscopy techniques give great details on the cell itself,
but little on the mechanism by which the observed effects are caused.
3. Flow cytometry: High-throughput technique
A common limitation of the techniques presented above is their throughput. Flow cytome-
try can provide statistical information on a large number155,204 of cells, simultaneously. It
makes use of similar dyes as these added for fluorescence imaging. Flow cytometry, however,
suffers from some of the same limitations as SEM, TEM, or AFM: it provides a snapshot of
the cell properties at a given time point after the experiment. It requires a sample preparation
step that may alter the cells, and its results are difficult to directly correlate to the local micros-
copy observations.
FIG. 4. (A) Confocal images of membrane perforation and resealing in microbubble-induced sonoporation (Reprinted with
permission from Hu et al., Ultrasound Med. Biol. 39, 2393 (2013). Copyright 2013 Elsevier). Upon the application of an
ultrasound pulse, a disruption of 5.3m is created in the cell, exactly at the site where the microbubble was. The cell mem-
brane is stained with an orange dye (CellMask Orange). After ultrasound exposure, the pore progressively reseals within a
few minutes. (B) SEM images of cell membrane damage after ultrasound radiation (Reprinted with permission from Kudo
et al., Biophys. J. 96, 4866 (2009). Copyright 2009 Elsevier). The high magnification views show perforations in the cell
membrane surrounded by a rough surface.
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Similar methods exist that make use of non-fluorescent dyes for viability examinations of a
cell population.204,205
V. SUMMARYAND OUTLOOK
There is a growing scientific literature demonstrating the unique potential of microbubbles
for targeted therapeutic delivery. However, a much more complete understanding of the funda-
mental mechanisms underlying microbubble-cell interactions is required to translate this poten-
tial into clinical benefit. Elucidating these interactions represents a significant challenge owing
to the complexity of the interactions and the range of timescales and length scales involved,
and consequently the range of different methods and techniques required to study them (Fig. 5).
In this paper, we have reviewed the available experimental methods. First, we have
described various cell models exhibiting different levels of complexity, and ranging from indi-
vidual cells up to more complex 3D cellular models, typically implemented in an organ-on-a-
chip format. Each model carries specific interest for the understanding of either the fundamen-
tals of bubble-cell interactions or that of the chain of events occurring on a larger scale.
Following this, we have reviewed various types of microbubbles and precursors that are cur-
rently used in research and in preclinical setting. We have presented their differences in activa-
tion, their behavior, and their potential. These bubbles can also target specific cells and are
therefore mostly relevant in combination with these specific cell models. Finally, based on an
appropriate combination of a cell model and a bubble type, we have reviewed the great variety
of experimental methods which have been reported in literature for studying bubble-cell interac-
tions, to yield specific information on the various physical and biological time scales and length
scales.
The development of ultra high-speed imaging systems has offered unparalleled insight into
microbubble dynamics, including the release and transport of model drugs and physical interac-
tions with biological structures. Similarly, real-time fluorescence microscopy techniques com-
bined with novel molecular probes have enabled membrane dynamics and sub-cellular proc-
esses to be studied, revealing hitherto unsuspected mechanisms of interaction and with
significant implications for both treatment efficacy, outcome, as well as safety. Technology in
FIG. 5. Summary of the diverse techniques used for the study of bubble-cell interaction in relation with the accessible time
scales and length scales. The left panel presents techniques that can be used simultaneously with the ultrasound exposure,
while the right panel shows the techniques that cannot be applied during ultrasound exposure and thus require a 2-step
experiment.
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both of these areas continues to advance rapidly and will undoubtedly facilitate further and
deeper understanding in the near future. Recent examples include the use of ultra high-speed
fluorescence microscopy to reveal the details of drug transport and uptake around oscillating
microbubbles and of live confocal microscopy to observe the dynamics of individual cell mem-
branes following cavitation events.206 Miniaturization of ultrasound devices and improved con-
trol over microbubble and microbubble precursor fabrication will similarly enable the design of
more versatile experimental systems to investigate these phenomena.
Each of the aforementioned techniques has the ability to elucidate specific aspects of
microbubble-cell interactions, and an important challenge of future experimental work will be
the ability to integrate these methods to be able to relate and correlate the different time and
length scales. This in combination with the newly developed cell models will greatly increase
the relevance of in vitro research on the interaction of bubbles with tissue in vivo. Similarly,
advances in endoscopy and intravital microscopy will ultimately enable these studies to bridge
to in vivo models so that microbubble-cell interactions can be studied in situ.
A detailed understanding of the underlying mechanisms will translate into the design of
more effective delivery agents, treatment protocols, and monitoring strategies and ultimately the
realization of microbubble-mediated therapy as a powerful new clinical approach.
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